Search
Alaproclate
go.drugbank.com/drugs/DB13233ExperimentalAlaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. … Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnIt reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with … Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target
Tesamorelin
go.drugbank.com/drugs/DB08869ApprovedInvestigationalTesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients
Synonyms: N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet)Etacrynic acid
go.drugbank.com/drugs/DB00903ApprovedInvestigationalA compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules.
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalIn addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects. … YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMolnupiravir
go.drugbank.com/drugs/DB15661Investigational[A193026] The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. … [A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to
Phenoxyethanol
go.drugbank.com/drugs/DB11304ApprovedInvestigationalPhenoxyethanol (EU), or PE, is the most commonly used globally-approved preservative in personal care formulations. It is very easy to use in various types of formulations and is chemically stable. … This substance occurs naturally in green tea (EU) [L2621].
Dipyrithione
go.drugbank.com/drugs/DB11327Approved[A32825] It may be combined with other ingredients, such as triclosan to serve as antifungal and antibacterial skin treatments. … [L2615] Dandruff is a common scalp disease affecting >40% of the world's adult population, and may be caused by fungi such as _Malassezia globosa_ and _M. restricta_.[A32162]
Adenosine phosphate
go.drugbank.com/drugs/DB00131ApprovedInvestigationalNutraceuticalWithdrawnAdenosine phosphate, or adenylic acid, is an adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. … Adenosine phosphate was withdrawn by the FDA since it was considered neither safe nor effective for its intended uses as a vasodilator and an anti-inflammatory.[L43937]
Synonyms: Fosfato de adenosina